Posted by Michael Wonder on 11 May 2021
MHRA approves label extension for Vertex’s Kaftrio combo
11 May 2021 - The UK MHRA has approved a label extension for Vertex’s cystic fibrosis treatment Kaftrio in combination with ivacaftor.
Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is now available in Great Britain for the treatment of cystic fibrosis in all patients aged 12 years and older, who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
